The startup that wants to cure diseases and slow aging, with the help of AI (CEO, document)
Please register to participate in our discussions with 2 million other members - it's free and quick! Some forums can only be seen by registered members. After you create your account, you'll be able to customize options and access all our 15,000 new posts/day with fewer ads.
In 2019, Insilico Medicine CEO Alex Zhavoronkov hired a film crew to document his biotech firm’s death in case its bold bet on a new drug didn’t pan out.
He was about to go all in on a potential new treatment for idiopathic pulmonary fibrosis, a lung disease that usually affects the elderly. While a biotech firm going bust after making a bad bet is not unusual, this drug was unique: It had been discovered using artificial intelligence.
“I wanted to leave some kind of legacy,” Zhavoronkov told Semafor.
Insilico didn’t die and ended up being one of the early computational biology startups in a field that is now exploding, as several breakthroughs in AI speed up the pace of innovation in biotech.
Please register to participate in our discussions with 2 million other members - it's free and quick! Some forums can only be seen by registered members. After you create your account, you'll be able to customize options and access all our 15,000 new posts/day with fewer ads.
